These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15599140)

  • 1. Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.
    Macias WL; Vallet B; Bernard GR; Vincent JL; Laterre PF; Nelson DR; Derchak PA; Dhainaut JF
    Crit Care Med; 2004 Dec; 32(12):2385-91. PubMed ID: 15599140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
    Dhainaut JF; Laterre PF; LaRosa SP; Levy H; Garber GE; Heiselman D; Kinasewitz GT; Light RB; Morris P; Schein R; Sollet JP; Bates BM; Utterback BG; Maki D
    Crit Care Med; 2003 Sep; 31(9):2291-301. PubMed ID: 14501959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
    Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
    Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
    Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
    Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
    Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
    Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
    Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
    Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
    Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
    Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
    Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
    Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
    Laterre PF; Garber G; Levy H; Wunderink R; Kinasewitz GT; Sollet JP; Maki DG; Bates B; Yan SC; Dhainaut JF;
    Crit Care Med; 2005 May; 33(5):952-61. PubMed ID: 15891319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
    Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
    N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
    McCoy C
    Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Fry DE; Beilman G; Johnson S; Williams MD; Rodman G; Booth FV; Bates BM; McCollam JS; Lowry SF;
    Surg Infect (Larchmt); 2004; 5(3):253-9. PubMed ID: 15684796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
    Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
    Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
    Frampton JE; Foster RH
    Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
    Yan SB; Nelson DR
    Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS.
    Richards G; Levy H; Laterre PF; Feldman C; Woodward B; Bates BM; Qualy RL
    J Intensive Care Med; 2011; 26(1):34-40. PubMed ID: 21341394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Static and dynamic assessment of biomarkers in surgical patients with severe sepsis.
    Lowry SF; Awad S; Ford H; Cheadle W; Williams MD; Qualy RL; McCollam JS; Bates BM; Fry DE;
    Surg Infect (Larchmt); 2004; 5(3):261-8. PubMed ID: 15684797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.